<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37344230</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS: Post Hoc Analysis of the EMPOWER Trial.</ArticleTitle><Pagination><StartPage>e690</StartPage><EndPage>e698</EndPage><MedlinePgn>e690-e698</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207485</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Polyunsaturated fatty acids (PUFAs) have neuroprotective and anti-inflammatory effects and could be beneficial in amyotrophic lateral sclerosis (ALS). Higher dietary intake and plasma levels of PUFAs, in particular alpha-linolenic acid (ALA), have been associated with a lower risk of ALS in large epidemiologic cohort studies, but data on disease progression in patients with ALS are sparse. We examined whether plasma levels of ALA and other PUFAs contributed to predicting survival time and functional decline in patients with ALS.</AbstractText><AbstractText Label="METHODS">We conducted a study among participants in the EMPOWER clinical trial who had plasma samples collected at the time of randomization that were available for fatty acid analyses. Plasma fatty acids were measured using gas chromatography. We used Cox proportional hazards models and linear regression to evaluate the association of individual fatty acids with risk of death and joint rank test score of functional decline and survival.</AbstractText><AbstractText Label="RESULTS">Fatty acid analyses were conducted in 449 participants. The mean (SD) age of these participants at baseline was 57.5 (10.7) years, and 293 (65.3%) were men; 126 (28.1%) died during follow-up. Higher ALA levels were associated with lower risk of death (age-adjusted and sex-adjusted hazard ratio comparing highest vs lowest quartile 0.50, 95% CI 0.29-0.86, <i>p</i>-trend = 0.041) and higher joint rank test score (difference in score according to 1 SD increase 10.7, 95% CI 0.2-21.1, <i>p</i> = 0.045), consistent with a slower functional decline. The estimates remained similar in analyses adjusted for body mass index, race/ethnicity, symptom duration, site of onset, riluzole use, family history of ALS, predicted upright slow vital capacity, and treatment group. Higher levels of the n-3 fatty acid eicosapentaenoic acid and the n-6 fatty acid linoleic acid were associated with a lower risk of death during follow-up.</AbstractText><AbstractText Label="DISCUSSION">Higher levels of ALA were associated with longer survival and slower functional decline in patients with ALS. These results suggest that ALA may have a favorable effect on disease progression in patients with ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bjornevik</LastName><ForeName>Kjetil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA. kbjorne@hsph.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortese</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtado</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarzschild</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascherio</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition (K.B., M.C., J.D.F., A.A.), and Department of Epidemiology (K.B., A.A.), Harvard T.H. Chan School of Public Health, Boston; Epidemiology (J.D.F.), Biogen, Cambridge; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Healey Center for ALS, Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.); Department of Neurology (M.A.S.), Massachusetts General Hospital; Sean M Healey &amp; AMG Center for ALS (M.E.C.), Mass General Hospital, Harvard Medical School; and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005231">Fatty Acids, Unsaturated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043371">Fatty Acids, Omega-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2023 Aug;19(8):459</RefSource><PMID Version="1">37402803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005231" MajorTopicYN="N">Fatty Acids, Unsaturated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="Y">Fatty Acids, Omega-3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043371" MajorTopicYN="N">Fatty Acids, Omega-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>K. Bjornevik reports no disclosures. M. Cortese has received a speaker honorarium from Roche. J.D. Furtado is currently an employee of and holds stock/stock options in Biogen. S. Paganoni reports research grants from Amylyx Pharmaceuticals, Revalesio Corporation, UCB, Biohaven, Clene, Seelos, and Prilenia and consulting fees from Orion, Cytokinetics, and Medscape. M.A. Schwarzschild received payment for consultative service from Denali, Lilly, Prevail, and the Parkinson Study Group (for advising Bial, Biogen, Chase Therapeutics, and Partner Therapeutics). M.E. Cudkowicz provided consultation to Avexis, Sunovion, Takeda, Biogen, Anelixis, Aclipse, Cytokinetics, Disarm, ALS Pharma, RRD, Immunity Pharma, Helixsmith, Denali, Wave, Orion, Transposon, QurAlis, Faze, Regeneron, AB Sciences, Lilly, MTPC, Locust Walk, and NeuroSense. She is on the board of directors for Praxis. A. Ascherio reports no disclosures. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37344230</ArticleId><ArticleId IdType="pmc">PMC10437021</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207485</ArticleId><ArticleId IdType="pii">WNL.0000000000207485</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/s0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15(12):771-785. doi:10.1038/nrn3820</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3820</ArticleId><ArticleId IdType="pubmed">25387473</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52. doi:10.3389/fnagi.2015.00052</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00052</ArticleId><ArticleId IdType="pmc">PMC4404917</ArticleId><ArticleId IdType="pubmed">25954194</ArticleId></ArticleIdList></Reference><Reference><Citation>Trepanier MO, Hopperton KE, Orr SK, Bazinet RP. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: an update. Eur J Pharmacol. 2016;785:187-206. doi:10.1016/j.ejphar.2015.05.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.05.045</ArticleId><ArticleId IdType="pubmed">26036964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet M, Calon F, Cicchetti F. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev. 2011;10(4):453-463. doi:10.1016/j.arr.2011.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2011.03.001</ArticleId><ArticleId IdType="pubmed">21414422</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Martinez-Coria H, Khashwji H, et al. . Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007;27(16):4385-4395. doi:10.1523/jneurosci.0055-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0055-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672302</ArticleId><ArticleId IdType="pubmed">17442823</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegert E, Paul F, Rothe M, Weylandt KH. The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. BMC Neurosci. 2017;18(1):19. doi:10.1186/s12868-016-0312-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-016-0312-5</ArticleId><ArticleId IdType="pmc">PMC5259863</ArticleId><ArticleId IdType="pubmed">28114887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip PK, Pizzasegola C, Gladman S, et al. . The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626. doi:10.1371/journal.pone.0061626</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061626</ArticleId><ArticleId IdType="pmc">PMC3631166</ArticleId><ArticleId IdType="pubmed">23620776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KC, O'Reilly EJ, Falcone GJ, et al. . Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(9):1102-1110. doi:10.1001/jamaneurol.2014.1214</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1214</ArticleId><ArticleId IdType="pmc">PMC4160351</ArticleId><ArticleId IdType="pubmed">25023276</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Kalmijn S, Groeneveld GJ, et al. . Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2006;78(4):367-371. doi:10.1136/jnnp.2005.083378</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083378</ArticleId><ArticleId IdType="pmc">PMC2077791</ArticleId><ArticleId IdType="pubmed">16648143</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Kihira T, Kondo T, et al. . Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph Lateral Scler. 2007;8(5):300-304. doi:10.1080/17482960701472249</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701472249</ArticleId><ArticleId IdType="pubmed">17852010</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly EJ, Bjornevik K, Furtado JD, et al. . Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis. Neurology. 2020;94(8):e811-e819. doi:10.1212/wnl.0000000000008676</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000008676</ArticleId><ArticleId IdType="pmc">PMC7136057</ArticleId><ArticleId IdType="pubmed">31796528</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieves JW, Gennings C, Factor-Litvak P, et al. . Association between dietary intake and function in amyotrophic lateral sclerosis. JAMA Neurol. 2016;73(12):1425-1432. doi:10.1001/jamaneurol.2016.3401</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.3401</ArticleId><ArticleId IdType="pmc">PMC5370581</ArticleId><ArticleId IdType="pubmed">27775751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al. . Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059-1067. doi:10.1016/s1474-4422(13)70221-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Baylin A, Kim MK, Donovan-Palmer A, et al. . Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol. 2005;162(4):373-381. doi:10.1093/aje/kwi213</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwi213</ArticleId><ArticleId IdType="pubmed">16014782</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. . The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162-168. doi:10.3109/21678421.2012.762930</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. doi:10.1080/01621459.1958.10501452</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1958.10501452</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686-1689. doi:10.1016/s0140-6736(02)08594-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(02)08594-x</ArticleId><ArticleId IdType="pubmed">12020548</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. 2021. Accessed March 3, 2023. R-project.org.</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, et al. . Welcome to the Tidyverse. J Open Sourc Softw. 2019;4(43):1686. doi:10.21105/joss.01686</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM. A Package for Survival Analysis in R. 2021. Accessed March 3, 2023. cran.r-project.org/package=survival.</Citation></Reference><Reference><Citation>Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves Using &#x2018;ggplot2&#x2019;. 2021. Accessed March 3, 2023. cran.r-project.org/package=survminer.</Citation></Reference><Reference><Citation>Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol. 1992;135(10):1114-1126; discussion 1127-1136. doi:10.1093/oxfordjournals.aje.a116211</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a116211</ArticleId><ArticleId IdType="pubmed">1632423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch AM, Loane DJ, Minogue AM, et al. . Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol Aging. 2007;28(6):845-855. doi:10.1016/j.neurobiolaging.2006.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.04.006</ArticleId><ArticleId IdType="pubmed">16714069</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69. doi:10.1038/nrn2038</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2038</ArticleId><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjorth E, Zhu M, Toro VC, et al. . Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-&#x3b2;42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697-713. doi:10.3233/jad-130131</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-130131</ArticleId><ArticleId IdType="pubmed">23481688</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657-673. doi:10.1038/s41577-022-00684-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00684-6</ArticleId><ArticleId IdType="pmc">PMC8895080</ArticleId><ArticleId IdType="pubmed">35246670</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157-172. doi:10.1038/s41582-020-00435-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00435-y</ArticleId><ArticleId IdType="pubmed">33318676</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005. doi:10.3389/fimmu.2017.01005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr. 2007;85(2):385-391. doi:10.1093/ajcn/85.2.385</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/85.2.385</ArticleId><ArticleId IdType="pubmed">17284733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A. Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis. 2003;167(2):237-242. doi:10.1016/s0021-9150(02)00427-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0021-9150(02)00427-6</ArticleId><ArticleId IdType="pubmed">12818406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr. 2011;141(12):2166-2171. doi:10.3945/jn.111.142240</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.111.142240</ArticleId><ArticleId IdType="pmc">PMC3223874</ArticleId><ArticleId IdType="pubmed">22031659</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. 2017;17(1):49-59. doi:10.1038/nri.2016.123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.123</ArticleId><ArticleId IdType="pubmed">27916979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, et al. . Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. doi:10.1038/s41598-017-09097-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett W. Nutritional Epidemiology, 3rd ed. Oxford University Press; 2013.</Citation></Reference><Reference><Citation>Baylin A, Campos H. The use of fatty acid biomarkers to reflect dietary intake. Curr Opin Lipidol. 2006;17(1):22-27. doi:10.1097/01.mol.0000199814.46720.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mol.0000199814.46720.83</ArticleId><ArticleId IdType="pubmed">16407712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA, et al. . Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065-2072. doi:10.1016/s0140-6736(14)60222-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>